Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.

FDA Priority Review was granted for trastuzumab deruxtecan in post-neoadjuvant HER2-positive early breast cancer with residual invasive disease, with a regulatory decision anticipated in Q3 2026.

Over the past six years, artificial intelligence has been significantly influenced by 12 foundational research papers. One ...

You'll choose either the Coalition Application (powered by Scoir) or the Common Application. We encourage each applicant to express their unique personality and diverse array of life experiences ...